Anavex working on Cancer and Alzheimer's, Two Biggest Health Concerns (AVXL, BIBB, AEN)
Psychology Today focuses Investor Attention on Companies in Neurological Diseases such as Anavex
Anyone investor who buys the most recent issue of Psychology Today and reads the article by Nikhil Swainathan, "How to Save Your Brain," will surely look at shares of Adeona Pharmaceuticals (AMEX: AEN ) and Biogen (NASDQ: BIIB) with special attention being due for Anavex Life Sciences (OTC: AVXL).
Swainathan terms neurological diseases and cancer as the two major health concerns of those living in the industrialized West. Anavex Life Sciences is a biopharmaceutical company engaged in the discovery and development of new drugs for the treatment of neurological diseases and cancer, utilizing its proprietary drug discovery SIGMACEPTOR™ platform.
What separates the Anavex portfolio from Adeona Pharmaceuticals (ADN) and Biogen (BII) is its novel, wholly owned sigma receptor agonists and antagonists. The lead drug candidate for Alzheimer’s Disease from Anaxex is ANAVEX 2-73. A Phase 1 single ascending dose (SAD) clinical trial has been completed successfully.
While previous treatments from the medical community have failed for Alzheimer's, Anavex's has started scale-up manufacturing for ANAVEX 1-41, its second lead compound, targeting depression and AD. That is what is known as an opportunity for investors. Anavex will be able to advance the program and begin preclinical studies on large animals when needed quantities are available. This is expected to be sooner, rather than later.
According to Swainathan's Psychology Today piece, "...the vast majority of Alzhemier cases -over 99 percent- occur spontaneously; they are not linked to genetic factors." That means that treatments and lifestyle changes can save many from the ravages of the disease.
A recent survey by the Harvard University School of Public Health and the Alzheimer European Consortium revealed the significance of the work of Anavex, Biogene and Adeona Pharmaceuticals. This offers investors the opportunity to both make good and do good. Anavex Life Sciences is one stock for both.
Jonathan Yates is a paid contributor of the SmallCap Network. Jonathan Yates's personal holdings should be disclosed above. You can also view SmallCap Network's complete disclaimer and disclosure.
